1. Home
  2. BW vs CHRS Comparison

BW vs CHRS Comparison

Compare BW & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Babcock & Wilcox Enterprises Inc.

BW

Babcock & Wilcox Enterprises Inc.

HOLD

Current Price

$19.49

Market Cap

2.7B

Sector

Industrials

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.54

Market Cap

296.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BW
CHRS
Founded
1867
2010
Country
United States
United States
Employees
1650
N/A
Industry
Building Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
296.8M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
BW
CHRS
Price
$19.49
$1.54
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$8.00
$5.51
AVG Volume (30 Days)
3.8M
1.3M
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$41.58
$73.08
Revenue Next Year
$66.70
$30.94
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.62
$0.72
52 Week High
$22.03
$2.62

Technical Indicators

Market Signals
Indicator
BW
CHRS
Relative Strength Index (RSI) 58.49 39.79
Support Level $13.54 $1.21
Resistance Level N/A $1.80
Average True Range (ATR) 1.94 0.11
MACD 0.33 -0.03
Stochastic Oscillator 69.59 11.63

Price Performance

Historical Comparison
BW
CHRS

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: